Lysogene: placed in liquidation and delisted
The company, which was already in receivership, informs that the listing of its shares, which had been suspended since early January, will not resume, and that an application for delisting will be made shortly to Euronext.
Following the failure of its Phase II/III study on its gene therapy for MPS IIIA, a rare recessive neurodegenerative disease, the company had run out of cash and no buyer had come forward.
Introduced at a unit price of 6.80 euros per share in 2017, the share price was less than 0.3 euros in recent trading.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction